Maribel Health, a company that helps healthcare systems design, build and operate technology-enabled clinical care services in the home and community, secured $25 million in a Series A funding round led by General Catalyst.
The New Hampshire-based company was formed as part of General Catalyst “Hatch” programwhere the venture capital firm provides resources to start businesses from the ground up and then works with them as they grow.
Maribel Health provides clinical workflow, training, technology, operational capacity and automation for remote clinical care teams as an extension of a healthcare system or outpatient clinic.
The company also announced partnerships with a St. Louis-based company Mercy Health System and New Jersey-based BAYADA Home Health Care, where Maribel will design, develop and manage home health care programs that will ultimately form the basis for other home health care models.
The funds will be used to accelerate growth with the company’s existing partners, onboard new talent and further develop its technology platform.
“Together, with our shared vision of health assurance, we have built Maribel: a technology-enabled operating partner with a mission to work within health systems to integrate advanced home and community-based care,” Hemant Taneja, CEO and general manager of General Catalyst, said in a Explanation. “Maribel is the latest hatch company to leverage GC’s creation strategy and join our early successes in building the company, namely Livongo, Commure, Kayak and Homeward. We believe this paradigm shift towards meeting people where they are will improve the quality of care and increase the overall capacity of the healthcare system.”
Dublin-based connected medical device company Fire1 closed a $25 million funding round led by Andera Partners and Novo Holdings.
Also participating in the round were existing investors Gilde Healthcare, Ireland Strategic Investment Fund, New Enterprise Associates, Lightstone Ventures, Gimv, Medtronic and Seventure Partners.
Aneta Sottil, director at Andera Life Sciences, and Eric Snyder, partner in venture investing at Novo Holdings, will join the company’s board of directors.
The company offers an implant that allows remote monitoring of heart failure patients. Fire1 will use the funds to accelerate the development of its remote monitoring solution.
Protaian AI-enabled drug discovery platform, announced that it has increased its seed funding by $12 million, bringing the total to $20 million.
Existing investors Grove Ventures and Pitango HealthTech joined the round alongside Copenhagen-based Maj Invest Equity Fund.
The Israeli company analyzes biomarkers at the protein level using its proteomics AI-based platform to map the course of a disease to help researchers in drug discovery and predict which patients will respond to a given drug.
The company will use the additional funds to build its oncology drug discovery pipeline, increase its activity through pharma partnerships, and expand its data collection.
The funds are in addition to those of the company Received $8 million in seed funding in 2022.
Salim Ismail will provide more details in his HIMSS23 presentation, Executive Summit Keynote: Disruptive Convergence. It is scheduled for Monday, April 17 at 3:45 – 4:30 pm CT at the Marriott Marquis Chicago, Level 4, in the Grand Horizon Ballroom.
